These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3118800)

  • 1. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.
    Schryvers AB; Ogunariwo J; Chamberland S; Godfrey AJ; Rabin HR; Bryan LE
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1438-9. PubMed ID: 3118800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
    Paull A; Morgan JR
    J Antimicrob Chemother; 1986 Nov; 18(5):635-9. PubMed ID: 3100487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
    Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
    Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
    Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
    J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
    Aktaş Z; Satana D; Kayacan C; Can B; Gönüllü N; Küçükbasmacı O
    Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase.
    Bagge N; Ciofu O; Skovgaard LT; Høiby N
    APMIS; 2000 Sep; 108(9):589-600. PubMed ID: 11110047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y
    Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
    Heilesen AM; Permin H; Koch C; Høiby N
    Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
    Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
    J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular epidemiology of beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates].
    Er H; Altındiş M; Aşık G; Demir C
    Mikrobiyol Bul; 2015 Apr; 49(2):156-65. PubMed ID: 26167816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams.
    Colque CA; Albarracín Orio AG; Tomatis PE; Dotta G; Moreno DM; Hedemann LG; Hickman RA; Sommer LM; Feliziani S; Moyano AJ; Bonomo RA; K Johansen H; Molin S; Vila AJ; Smania AM
    mBio; 2022 Oct; 13(5):e0166322. PubMed ID: 36073814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
    Watkins J; Francis J; Kuzemko JA
    Scand J Gastroenterol Suppl; 1988; 143():81-5. PubMed ID: 3133756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.